VERA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Based on the data provided, Vera Therapeutics Inc (VERA) is not a strong buy at this moment for a beginner, long-term investor with $50,000-$100,000 available for investment. While there are positive catalysts such as FDA priority review and a strong cash position, the technical indicators and insider selling trends suggest caution. Additionally, the stock's recent performance and lack of strong proprietary trading signals do not support an immediate buy decision.
The MACD is below zero and negatively contracting, indicating bearish momentum. RSI is neutral at 47.32, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level of 42.452, with support at 40.794 and resistance at 44.11. Overall, the technical indicators suggest a neutral to slightly bearish outlook.
FDA priority review for atacicept in IgA nephropathy, which could expedite market entry.
Strong cash position of $714 million, providing financial stability for future operations.
Analysts have raised price targets significantly, reflecting optimism about the company's potential.
Insider selling has increased by 158.76% over the last month, which could indicate a lack of confidence from management.
The stock has an 80% chance of declining in the short term based on candlestick pattern analysis.
The company reported a negative EPS of -$4.66, highlighting profitability challenges.
In Q4 2025, the company reported no revenue growth and a net loss of $91.1 million, though this was an improvement of 109.78% YoY. EPS also improved by 93.06% YoY but remains negative at -1.39. The company has a strong cash position of $714 million, which provides a financial cushion.
Analysts are generally bullish, with multiple firms raising price targets significantly (e.g., Goldman Sachs to $95, BofA to $66, JPMorgan to $96). The raised targets reflect optimism about the company's lead drug and its market potential. However, there is some divergence in opinions, with JPMorgan slightly lowering its target from $99 to $96.
